Clinical Trials
43 trialsNCT02523976 2026-02-11
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Completed
NCT03860844 2025-09-09
ISAKIDS
Sanofi
Phase 2 Terminated
NCT00004197 2023-09-07
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00712582 2022-06-21
Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00290511 2022-04-22
Rituximab, Fludarabine, Mitoxantrone, Dexamethasone (R-FND) Plus Zevalin for High-Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00193479 2022-03-03
Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT01186640 2022-01-05
Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL)
German CLL Study Group
Phase 2 Completed
NCT00901927 2020-04-03
Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02733380 2020-04-01
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
Henan Cancer Hospital
Phase 2 Unknown
NCT00169208 2019-08-28
Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma
Lymphoma Study Association
Phase 2 Completed
NCT02535806 2019-08-13
Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults
Children's Mercy Hospital Kansas City
Phase 2 Terminated
NCT00254410 2019-05-01
FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02518750 2019-04-03
Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00458848 2019-02-15
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Completed
NCT01133158 2018-11-01
R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Phase 2 Completed
NCT00274963 2018-05-11
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT00278213 2018-05-11
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
German CLL Study Group
Phase 2 Completed
NCT02419755 2018-03-07
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00005985 2017-11-29
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00005998 2017-11-29
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT00186875 2017-07-28
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00079105 2017-03-30
A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years
Newcastle-upon-Tyne Hospitals NHS Trust
Phase 2 Completed
NCT00656084 2016-11-03
Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell
US Oncology Research
Phase 2 Completed
NCT01144403 2016-10-18
A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma.
Hoffmann-La Roche
Phase 2 Terminated
NCT01578343 2016-04-15
ZOLINZA
Samsung Medical Center
Phase 2 Terminated
NCT01523860 2016-03-01
FLE09
Fondazione Italiana Linfomi - ETS
Phase 2 Completed
NCT01004497 2015-05-29
ALL
The Catholic University of Korea
Phase 2 Completed
NCT00109837 2015-03-25
S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00183989 2014-05-22
Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
University of Southern California
Phase 2 Terminated
NCT00510887 2014-05-12
Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma
Duke University
Phase 2 Terminated
NCT00119730 2014-04-24
Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00100477 2013-09-25
Use of Topotecan in Patients With Refractory Acute Leukemia
VA Office of Research and Development
Phase 2 Completed
NCT00002905 2013-09-20
Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00337246 2013-08-02
Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00842595 2013-07-24
Efficacy , Safety of Treatment R NIMP for Relapsed Aggressive Lymphomas
French Innovative Leukemia Organisation
Phase 2 Completed
NCT00003957 2013-04-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
Fox Chase Cancer Center
Phase 2 Completed
NCT00208975 2012-06-28
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Emory University
Phase 2 Terminated
NCT01513603 2012-01-20
Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia
New York Medical College
Phase 2 Unknown
NCT00053131 2011-03-08
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
Phase 2 Completed
NCT00047021 2010-06-11
Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00556127 2007-11-09
DLBCL
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Phase 2 Completed
NCT00002003 2005-06-24
Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas
NIH AIDS Clinical Trials Information Service
Phase 2 Completed